BOT 1.45% 34.0¢ botanix pharmaceuticals ltd

Ann: FDA Approves Sofdra, page-234

  1. 889 Posts.
    lightbulb Created with Sketch. 99
    The catalysts for DXB SP surge were the partnerships because they signal independent stamp of confidence in the company...
    That is exactly what the FDA approval means, even more than mere partnerships.

    In my opinion, this CR by BOT was very badly timed and clearly smells like they wanted to give cheap shares to their mates before the SP took off on FDA approval.

    Now the CR selling will dampen the momentum from the FDA approval.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
34.0¢
Change
-0.005(1.45%)
Mkt cap ! $615.4M
Open High Low Value Volume
34.0¢ 34.0¢ 32.8¢ $1.949M 5.840M

Buyers (Bids)

No. Vol. Price($)
1 2985 33.5¢
 

Sellers (Offers)

Price($) Vol. No.
34.0¢ 420471 4
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.